



MetrioPharm AG announces successful completion of the single-dose part of MP1032's first-in-man clinical trial

Zurich, July 15, 2015

MetrioPharm AG announces results of the single-dose part of its Phase I first-in-man clinical trial with its lead compound MP1032. Four groups of healthy volunteers received increasing single doses of MP1032 in a specialized German clinical trial site. Maximum dosages of 600 mg were applied with no occurrence of undesired side effects.

„We are very pleased with these results. They fully confirm our high expectations in the safety profile of orally administered MP1032. We are confident that MP1032 will continue to prove its safety and tolerability in upcoming clinical trials.“ commented Dr. Wolfgang Brysch, President of the Board of MetrioPharm AG.

Following the statistic evaluation of the results and sign-off by the responsible authority BfArM, the multi-dose part of the clinical trial is expected to begin in October. MetrioPharm AG will then test repeated dosing of MP1032 in healthy volunteers.

About MP1032

The proprietary drug candidate MP1032 is a synthetic small-molecule drug with strong anti-inflammatory properties and an excellent pre-clinical safety profile. MP1032 acts primarily through the modulation of macrophages, the main cells of the innate immune system. Macrophage modulators represent a new class of drugs that modulate inflammation with a very broad spectrum of potential clinical applications.

About MetrioPharm AG

MetrioPharm AG is a Swiss pharmaceutical company headquartered in Zurich. MetrioPharm AG is pioneering a new class of drugs for the treatment of chronic inflammatory diseases such as psoriasis, rheumatoid arthritis, or arthritis. The company's macrophage-modulating compound class is characterized by high anti-inflammatory efficacy and good tolerability.

Copyright © 2016 MetrioPharm AG, All rights reserved.
MetrioPharm AG Newsletter

Our mailing address is:
MetrioPharm AG
Bleicherweg 45, Zürich
Zürich 8002
Switzerland